Overview

Phase I Study of EOC237 in Patients With Advanced Solid Tumor

Status:
Not yet recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd